---
document_datetime: 2023-09-21 22:24:39
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nexpovio-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: nexpovio-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.7334751
conversion_datetime: 2025-12-28 18:21:47.155644
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Nexpovio

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0016               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                              | 14/08/2023                          |                                             | PL                               |           |
| IB/0014              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 03/07/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IAIN/0013           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 19/04/2023   | n/a   |                 |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------|-----------------------------------|
| PSUSA/10926 /202209 | Periodic Safety Update EU Single assessment - selinexor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/04/2023   | n/a   |                 | PRAC Recommendation - maintenance |
| II/0011             | Update of section 4.5 of the SmPC in order to add drug-drug interaction information regarding the strong CYP3A4 inhibitor, clarithromycin, based on results from the drug-drug interaction (DDI) pharmacokinetic (PK) portion of Study KCP 330-017 (STOMP) following procedure EMEA/H/C/005127/REC/003.1. This is a Phase 1b/2, multi-center, open-label, clinical study with Dose Escalation (Phase 1) and Expansion (Phase 2) to independently assess the MTD, efficacy, and safety of 10 combination therapies in 11 arms in patients with RRMM (Relapsed/Refractory Multiple Myeloma) and NDMM (Newly Diagnosed Multiple Myeloma). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/01/2023   |       | SmPC            | Not applicable                    |
| IAIN/0010/G         | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 11/11/2022   |       | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                           |            |            |                        |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10926 /202203 | Periodic Safety Update EU Single assessment - selinexor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 27/10/2022 | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0009/G         | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - | 22/09/2022 |            | Annex II and PL        |                                   |
| T/0007              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 24/06/2022 | 22/07/2022 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0001/G   | This was an application for a group of variations. • Extension of indication for Nexpovio in   | 19/05/2022   | 18/07/2022   | SmPC, Annex II, Labelling and PL   | Please refer to Scientific Discussion 'Nexpovio-H-C-5127-II- 0001/G'                                               |
|-------------|------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| IB/0006/G   | This was an application for a group of variations.                                             | 25/05/2022   | 22/07/2022   | SmPC and PL                        | C.I.z - To update the PL to include the name and address of the site responsible for batch release of the finished |

<div style=\"page-break-after: always\"></div>

|                     | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)   |            |            | product. B.II.f.1.b.1 - To extend the shelf-life of the finished product as packaged for sale from 48 months to 60 months.                                                                                                                                                                                                                               |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0005              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 24/03/2022 | 13/05/2022 | Positive Opinion adopted by consensus together with the CHMP assessment report ‹and translation timetable›. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion. |
| PSUSA/10926 /202109 | Periodic Safety Update EU Single assessment - selinexor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 05/05/2022 | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                        |
| IA/0003/G           | This was an application for a group of variations. B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16/11/2021 | n/a        |                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits A.z - Administrative change - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure   |            |            |      | changes to a   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------|
| IB/0002/G | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.c.z - Container closure system of the AS - Other variation B.I.b.z - Change in control of the AS - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale                                                                                                                                            | 10/09/2021 | 13/05/2022 | SmPC |                |

<div style=\"page-break-after: always\"></div>

| (supported by real time data)   |
|---------------------------------|